Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis due to RIG-I Hyperactivation

• Published in: Journal of the American Society of Nephrology Vol. 34; no. 2; pp. 258 - 272
• Main Authors: Peng, Jiahui, Wang, Yusha, Han, Xu, Zhang, Changming, Chen, Xiang, Jin, Ying, Yang, Zhaohui, An, Yu, Zhang, Jiahui, Liu, Zhengzhao, Chen, Yinghua, Gao, Erzhi, Zhang, Yangyang, Xu, Feng, Zheng, Chunxia, Zhou, Qing, Liu, Zhihong
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.02.2023
• Subjects: Basic Research; DEAD Box Protein 58 - genetics; DEAD Box Protein 58 - therapeutic use; Gene Expression Profiling; Genetic Disease of the Kidney; Humans; Interferon Type I; Lupus Erythematosus, Systemic; Lupus Nephritis; Receptors, Immunologic - genetics; Signal Transduction
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.2022040477

Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus, with heterogeneous phenotypes and different responses to therapy. Identifying genetic causes of LN can facilitate more individual treatment strategies. We performed whole-exome sequencing in a cohort of Chinese patients with LN and identified variants of a disease-causing gene. Extensive biochemical, immunologic, and functional analyses assessed the effect of the variant on type I IFN signaling. We further investigated the effectiveness of targeted therapy using single-cell RNA sequencing. We identified a novel DDX58 pathogenic variant, R109C, in five unrelated families with LN. The DDX58 R109C variant is a gain-of-function mutation, elevating type I IFN signaling due to reduced autoinhibition, which leads to RIG-I hyperactivation, increased RIG-I K63 ubiquitination, and MAVS aggregation. Transcriptome analysis revealed an increased IFN signature in patient monocytes. Initiation of JAK inhibitor therapy (baricitinib 2 mg/d) effectively suppressed the IFN signal in one patient. A novel DDX58 R109C variant that can cause LN connects IFNopathy and LN, suggesting targeted therapy on the basis of pathogenicity. This article contains a podcast at.